On the front tonightIHH Unit Appeals Tokyo Court Dismissal of $1.1B Daiichi Sankyo Claim
Today's story
Daiichi unit proposes A$7.9bn Challenger takeover
TAL Daiichi Life Australia offered A$11.80 a share for the rest of Challenger, valuing it at about A$7.94 billion; the board is reviewing the non-binding bid.
Business · 14 sources · 5hRead it
The journal
Open the journal →The conversation starts in the journal — be the first to post.
About Daiichi Sankyo
Daiichi Sankyo Company, Limited is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 1,278 billion in revenue in 2022. The company owns the American pharmaceutical company American Regent.
Everything about Daiichi Sankyo →- Country
- Japan
- Headquarters
- Chūō
- Inception
- 2005
- Website
- https://www.daiichisankyo.co.jp/